Table 2.
Comparison of clinicopathological characteristics of patients with pure DCIS between this and published studies.
| Characteristics | Subgroup | Our study | SEER 2015 | NSABP-B24 | EORTC | SweDCIS | B17 | Canada | Nottingham 2019 | UCSD 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year of research | — | 2005–2015 | 1988–2011 | 1986–2009 | 1986–1996 | 1987–1999 | 1985–1990 | 1994–2003 | 1990–2012 | 2010–2016 |
|
| ||||||||||
| No. of patients | — | 617 | 108.196 | 2.061 | 1010 | 1046 | 790 | 571 | 651 | 1540 |
|
| ||||||||||
| Detection method | Symptomatic | 58.7% | — | 8.7% | 27.2% | 27.6% | 8.1% | — | 48% | — |
| Screening | 39.4% | — | 82.6% | 71.6% | 72.4% | 80.8% | — | 52% | — | |
|
| ||||||||||
| Age (years) | ≤50 y | 56.7% | 33.9% | 33.5% | — | 24.1% | 33.3% | 19.3% | — | — |
| ＞50 y | 43.3% | 66.1% | 66.5% | — | 75.9% | 66.7% | 80.7% | — | — | |
|
| ||||||||||
| Tumor size (cm) | ≤2.0 cm | 78.1% | 77.0% | 94.2% | 91.2% | 67.5% | 87.8% | — | — | — |
| ＞2.0 cm | 21.9% | 23.0% | 4.3% | 8.8% | 21.8% | 8.9% | — | — | — | |
|
| ||||||||||
| Nuclear grade | Low-intermediate | 77.4% | 54.0% | 54.0% | 62.3% | 50.2% | — | 67.7% | 39.2% | 57.3% |
| High | 20.9% | 46.0% | 42.3% | 37.7% | 49.8% | — | 32.3% | 60.8% | 42.7% | |
|
| ||||||||||
| ER status | Positive | 76.3% | 42.5% | 28.6% | 52.7% | — | — | 94.7% | 75.3% | 84.2% |
| Negative | 19.3% | 8.2% | 8.3% | 19.8% | — | — | 5.3% | 24.7% | 15.5% | |
| NA | 4.4% | 49.2% | 63.1% | 27.5% | — | — | — | — | 0.3% | |
|
| ||||||||||
| PR status | Positive | 69.0% | — | — | 44.3% | — | — | — | 46.7% | 74.2% |
| Negative | 26.3% | — | — | 23.1% | — | — | — | 53.3% | 25.2% | |
| NA | 3.7% | — | — | 32.7% | — | — | — | — | 0.6% | |
SEER: surveillance, epidemiology, and end results; NSABP: National Surgical Adjuvant Breast and Bowel Project; EORTC: European Organisation for Research and Treatment of Cancer; SweDCIS: Swedish ductal carcinoma in situ; UCSD: University of California, San Diego; other abbreviations as in Table 1.